Compass Pathways plc
CMPS$355M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaCHESIRE166 employees
Drugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Feb 15, 2026
7dData is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
1 upcoming, 0 past
⭐Phase 3Next
Psilocybin Phase 3 Results Expected
February 2026~Psilocybin572
Primary completion for Psilocybin trial (NCT05711940) in Treatment Resistant Depression
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Psilocybin | Phase 3 | Treatment Resistant Depression | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
CMPS News